Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

About Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ACHN
  • CUSIP: 00448Q20
  • Web: www.achillion.com
Capitalization:
  • Market Cap: $667.4 million
  • Outstanding Shares: 136,761,000
Average Prices:
  • 50 Day Moving Avg: $4.44
  • 200 Day Moving Avg: $4.15
  • 52 Week Range: $3.15 - $9.49
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.71
  • P/E Growth: -0.42
Sales & Book Value:
  • Annual Revenue: $15 million
  • Price / Sales: 44.49
  • Book Value: $2.65 per share
  • Price / Book: 1.84
Profitability:
  • EBIDTA: ($70,510,000.00)
  • Return on Equity: -17.56%
  • Return on Assets: -16.97%
Debt:
  • Current Ratio: 25.33%
  • Quick Ratio: 25.33%
Misc:
  • Average Volume: 1.98 million shs.
  • Beta: 1.95
  • Short Ratio: 5.29
 

Frequently Asked Questions for Achillion Pharmaceuticals (NASDAQ:ACHN)

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) posted its earnings results on Tuesday, August, 8th. The company reported ($0.16) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.16). During the same quarter in the prior year, the business posted ($0.14) EPS. View Achillion Pharmaceuticals' Earnings History.

Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2017?

8 analysts have issued twelve-month target prices for Achillion Pharmaceuticals' shares. Their forecasts range from $4.00 to $16.00. On average, they expect Achillion Pharmaceuticals' stock price to reach $8.71 in the next twelve months. View Analyst Ratings for Achillion Pharmaceuticals.

Who are some of Achillion Pharmaceuticals' key competitors?

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:

  • David I. Scheer, Chairman of the Board
  • Milind S. Deshpande Ph.D., President, Chief Executive Officer, Director
  • Mary Kay Fenton CPA, Chief Financial Officer, Executive Vice President
  • Martha E. Manning Esq., Executive Vice President, General Counsel, Corporate Secretary
  • David Apelian M.D. Ph.D., Executive Vice President, Chief Medical Officer
  • Joseph Truitt, Executive Vice President, Chief Commercial Officer
  • Amy Jennings, Senior Vice President - Regulatory Affairs
  • Michael D. Kishbauch, Director
  • Frank Verwiel M.D., Director
  • Jason S. Fisherman M.D., Independent Director

Who owns Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include RA Capital Management LLC (9.97%), Vanguard Group Inc. (7.00%), Janus Henderson Group PLC (3.31%), State Street Corp (2.91%), Numeric Investors LLC (2.15%) and Dimensional Fund Advisors LP (1.37%). Company insiders that own Achillion Pharmaceuticals stock include David Apelian, Jason S Fisherman, Joel C Barrish, Mary Kay Fenton and Nicole Vitullo. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Who sold Achillion Pharmaceuticals stock? Who is selling Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, State Street Corp, Emory University, Numeric Investors LLC, PDT Partners LLC, Northern Trust Corp, Pacad Investment Ltd. and AXA. View Insider Buying and Selling for Achillion Pharmaceuticals.

Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Dimensional Fund Advisors LP, Senzar Asset Management LLC, EcoR1 Capital LLC, JPMorgan Chase & Co., FMR LLC, Los Angeles Capital Management & Equity Research Inc. and GSA Capital Partners LLP. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy Achillion Pharmaceuticals stock?

Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $4.88.


MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  280 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  483
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.63)
Consensus Price Target: $8.71 (78.57% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Robert W. BairdDowngradeOutperform -> Neutral$5.00HighView Rating Details
8/9/2017Maxim GroupSet Price TargetBuy$5.00 -> $7.00HighView Rating Details
8/9/2017Chardan CapitalLower Price TargetNeutral$5.00 -> $4.00HighView Rating Details
5/18/2017Leerink SwannUpgradeMarket Perform -> Outperform$4.00 -> $6.00HighView Rating Details
4/26/2017Jefferies Group LLCReiterated RatingHoldLowView Rating Details
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$10.00N/AView Rating Details
11/3/2016WedbushReiterated RatingOutperform$13.00N/AView Rating Details
9/15/2016FBR & CoInitiated CoverageOutperform$16.00N/AView Rating Details
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00N/AView Rating Details
12/8/2015William BlairReiterated RatingOutperform$16.00N/AView Rating Details
(Data available from 8/18/2015 forward)

Earnings

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Earnings by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Earnings History by Quarter for Achillion Pharmaceuticals (NASDAQ ACHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($0.16)($0.16)ViewListenView Earnings Details
5/4/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.18)($0.03)$15.00 millionViewN/AView Earnings Details
11/3/2016Q3($0.16)($0.15)ViewN/AView Earnings Details
8/4/2016Q2($0.15)($0.14)ViewN/AView Earnings Details
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details
3/5/2015Q414($0.19)($0.21)ViewN/AView Earnings Details
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details
5/7/2014Q114($0.17)($0.17)ViewN/AView Earnings Details
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)
2017 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.17)($0.16)($0.17)
Q2 20173($0.17)($0.17)($0.17)
Q3 20173($0.18)($0.18)($0.18)
Q4 20171($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 70.70%
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2016Jason S FishermanDirectorBuy10,000$3.96$39,600.00View SEC Filing  
12/5/2016Mary Kay FentonCFOBuy2,500$4.11$10,275.00View SEC Filing  
12/2/2016Joel C BarrishInsiderBuy2,500$4.06$10,150.00View SEC Filing  
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.00View SEC Filing  
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.20View SEC Filing  
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00View SEC Filing  
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.00View SEC Filing  
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.00View SEC Filing  
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.00View SEC Filing  
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Achillion Pharmaceuticals (NASDAQ:ACHN)
Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
Source:
DateHeadline
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 11 at 5:06 PM
finance.yahoo.com logoCorporate News Blog - Achillion Announces Proof-of-Concept with a First-in-Class, Oral Factor D Inhibitor
finance.yahoo.com - August 11 at 3:49 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 11 at 2:14 PM
americanbankingnews.com logoLeerink Swann Comments on Achillion Pharmaceuticals, Inc.'s FY2017 Earnings (ACHN)
www.americanbankingnews.com - August 11 at 12:04 PM
americanbankingnews.com logoWilliam Blair Research Analysts Cut Earnings Estimates for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)
www.americanbankingnews.com - August 11 at 12:04 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and ACADIA Pharmaceuticals
finance.yahoo.com - August 10 at 4:51 PM
finance.yahoo.com logoAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : August 10, 2017
finance.yahoo.com - August 10 at 4:51 PM
finance.yahoo.com logoAchillion Pharmaceuticals Stock Falls, Baird Downgrades Over Lack of Confidence
finance.yahoo.com - August 10 at 4:51 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Stock Rating Lowered by Robert W. Baird
www.americanbankingnews.com - August 10 at 2:16 PM
nasdaq.com logoHealth Care Sector Update for 08/09/2017: ACHN,NTRA,SGRY - Nasdaq
www.nasdaq.com - August 10 at 1:48 AM
finance.yahoo.com logoEdited Transcript of ACHN earnings conference call or presentation 8-Aug-17 8:05pm GMT
finance.yahoo.com - August 9 at 8:46 PM
finance.yahoo.com logoAchillion (ACHN) Q2 Loss In Line, Gains on Pipeline Update
finance.yahoo.com - August 9 at 8:46 PM
finance.yahoo.com logo3 Biotech Stocks Under the Microscope on Wednesday 8/9/17
finance.yahoo.com - August 9 at 8:46 PM
americanbankingnews.com logoMaxim Group Analysts Give Achillion Pharmaceuticals, Inc. (ACHN) a $7.00 Price Target
www.americanbankingnews.com - August 9 at 6:46 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Releases Earnings Results, Meets Expectations
www.americanbankingnews.com - August 9 at 4:08 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE-Priceline, Hertz, Natera, Surgical Partners - Nasdaq
www.nasdaq.com - August 9 at 3:44 PM
finance.yahoo.com logo2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
finance.yahoo.com - August 9 at 3:44 PM
fool.com logoWhy Achillion Pharmaceuticals Is Shooting 25% Higher Today
www.fool.com - August 9 at 2:04 PM
fool.com logo2 Reasons Behind Achillion Pharmaceuticals, Inc.'s 11% Tumble in July
www.fool.com - August 9 at 2:04 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Price Target Cut to $4.00
www.americanbankingnews.com - August 9 at 9:00 AM
marketwatch.com logoAchillion shares rally as blood disorder treatment shows promise - MarketWatch
www.marketwatch.com - August 9 at 1:33 AM
seekingalpha.com logoAchillion Pharmaceuticals' (ACHN) CEO Milind Deshpande on Q2 ... - Seeking Alpha
seekingalpha.com - August 9 at 1:33 AM
finance.yahoo.com logoAchillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor
finance.yahoo.com - August 8 at 8:27 PM
finance.yahoo.com logoAchillion shares rally as blood disorder treatment shows promise
finance.yahoo.com - August 8 at 8:27 PM
finance.yahoo.com logoAchillion reports 2Q loss
finance.yahoo.com - August 8 at 8:27 PM
finance.yahoo.com logoInvestor Network: Achillion Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 8 at 3:26 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - August 5 at 11:58 PM
finance.yahoo.com logoAchillion to Host Second Quarter 2017 Results Conference Call on August 8, 2017
finance.yahoo.com - August 1 at 8:38 PM
finance.yahoo.com logoAchillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : August 1, 2017
finance.yahoo.com - August 1 at 8:38 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:10 AM
americanbankingnews.com logo Analysts Anticipate Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to Post -$0.16 EPS
www.americanbankingnews.com - July 24 at 10:19 PM
nasdaq.com logoIs the Options Market Predicting a Spike in Achillion Pharmaceuticals (ACHN) Stock? - Nasdaq
www.nasdaq.com - July 20 at 3:27 PM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Achillion Pharmaceuticals (ACHN) Stock?
finance.yahoo.com - July 20 at 3:27 PM
finance.yahoo.com logoAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : July 19, 2017
finance.yahoo.com - July 19 at 3:33 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - July 18 at 8:32 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 10:49 AM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - July 11 at 10:14 PM
streetinsider.com logoAchillion Pharma (ACHN) Mingjun Huang Promoted to SVP & Head ... - StreetInsider.com
www.streetinsider.com - July 10 at 8:34 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - July 8 at 2:21 PM
seekingalpha.com logoBiotechs head higher ahead of Q2 earnings dump - Seeking Alpha
seekingalpha.com - July 5 at 3:33 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Expected to Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - June 28 at 6:26 PM
finance.yahoo.com logoAchillion Pharmaceuticals Financials, Price Targets and Pipeline Review
finance.yahoo.com - June 22 at 1:05 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 20 at 8:34 AM
globenewswire.com logoAchillion to Present at the 2017 JMP Securities Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 16 at 3:31 PM
finance.yahoo.com logoAchillion to Present at the 2017 JMP Securities Life Sciences Conference
finance.yahoo.com - June 15 at 8:27 PM
finance.yahoo.com logoAchillion (ACHN) Up 31.1% Since Earnings Report: Can It Continue?
finance.yahoo.com - June 9 at 3:21 PM
finance.yahoo.com logoAchillion to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 5 at 6:18 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and TG Therapeutics
finance.yahoo.com - June 5 at 1:16 PM
americanbankingnews.com logoAchillion Pharmaceuticals, Inc. (ACHN) Short Interest Update
www.americanbankingnews.com - May 27 at 7:06 AM
prnewswire.com logoBiotech Stocks on Investors' Radar -- Achillion Pharma, Acorda ... - PR Newswire (press release)
www.prnewswire.com - May 26 at 3:18 PM

Social

Chart

Achillion Pharmaceuticals (ACHN) Chart for Friday, August, 18, 2017

This page was last updated on 8/18/2017 by MarketBeat.com Staff